Who are dapsone gel vehicle's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aczone Gel, Dapsone Topical Gel + vehicle control, Dapsone 7.5 % gel, Dapsone 5.0% Gel (SEEGPharm), Dapsone 5.0% Gel (Allergan).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dapsone-gel-vehicle.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

dapsone gel vehicle — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

dapsone gel vehicle (dapsone gel vehicle) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfone antibiotic with anti-inflammatory properties. Area: Dermatology.

phase 3 Sulfone antibiotic with anti-inflammatory properties Dihydropteroate synthase; neutrophil function modulation Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

dapsone gel vehicle (dapsone gel vehicle) — Almirall, S.A.. Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties, reducing neutrophil migration and reactive oxygen species production.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
dapsone gel vehicle TARGET	dapsone gel vehicle	Almirall, S.A.	phase 3	Sulfone antibiotic with anti-inflammatory properties	Dihydropteroate synthase; neutrophil function modulation
Aczone Gel	Aczone Gel	Icahn School of Medicine at Mount Sinai	marketed	Sulfone antibiotic	Bacterial dihydropteroate synthase; neutrophil function modulation
Dapsone Topical Gel + vehicle control	Dapsone Topical Gel + vehicle control	Allergan	phase 3	Sulfone antimicrobial and anti-inflammatory agent	Dihydropteroate synthase; neutrophil function modulation
Dapsone 7.5 % gel	Dapsone 7.5 % gel	Derm Research, PLLC	marketed	Sulfone antibiotic with anti-inflammatory properties	Dihydropteroate synthase; neutrophil function and inflammatory mediators
Dapsone 5.0% Gel (SEEGPharm)	Dapsone 5.0% Gel (SEEGPharm)	Seegpharm S.A.	phase 3	Sulfone antibiotic with anti-inflammatory properties	Dihydropteroate synthase (bacterial); neutrophil function and ROS production (host)
Dapsone 5.0% Gel (Allergan)	Dapsone 5.0% Gel (Allergan)	Seegpharm S.A.	phase 3	Sulfone antibiotic with anti-inflammatory properties	Dihydropteroate synthase (bacterial); neutrophil function and ROS production (host)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfone antibiotic with anti-inflammatory properties class)

Seegpharm S.A. · 2 drugs in this class
Almirall, S.A. · 1 drug in this class
Derm Research, PLLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). dapsone gel vehicle — Competitive Intelligence Brief. https://druglandscape.com/ci/dapsone-gel-vehicle. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing